Recently, the Category 1 innovative drug Envonalkib Citrate Capsules (trade name: 安洛晴) of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with anaplastic lymphoma kinase (ALK) inhibitors.

Envonalkib Citrate Capsule is a tyrosine kinase receptor inhibitor. The marketing of this drug provides a new treatment option for NSCLC patients.